Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.

Perman MJ, Lovell DJ, Denson LA, Farrell MK, Lucky AW.

Pediatr Dermatol. 2012 Jul-Aug;29(4):454-9. doi: 10.1111/j.1525-1470.2011.01521.x. Epub 2011 Oct 13.

PMID:
21995665
2.

Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.

Cullen G, Kroshinsky D, Cheifetz AS, Korzenik JR.

Aliment Pharmacol Ther. 2011 Dec;34(11-12):1318-27. doi: 10.1111/j.1365-2036.2011.04866.x. Epub 2011 Sep 29. Review.

3.

Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.

Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, González-Lama Y, López-Sanromán A, Manceñido N, Martínez-Montiel P, Quintanilla E, Taxonera C, Villafruela M, Romero-Maté A, López-Serrano P, Gisbert JP, Bermejo F.

J Crohns Colitis. 2012 Jun;6(5):518-23. doi: 10.1016/j.crohns.2011.10.007. Epub 2011 Nov 13.

PMID:
22398059
4.

Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature.

Osório F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H, Azevedo F, Magina S.

Dermatology. 2012;225(2):163-7. doi: 10.1159/000342503. Epub 2012 Oct 6. Review.

PMID:
23052429
5.

Adalimumab-induced psoriasis of the scalp with diffuse alopecia: a severe potentially irreversible cutaneous side effect of TNF-alpha blockers.

El Shabrawi-Caelen L, La Placa M, Vincenzi C, Haidn T, Muellegger R, Tosti A.

Inflamm Bowel Dis. 2010 Feb;16(2):182-3. doi: 10.1002/ibd.20954. No abstract available.

PMID:
19462433
6.

Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-α inhibitors: the Mayo Clinic experience, 1998 to 2010.

Shmidt E, Wetter DA, Ferguson SB, Pittelkow MR.

J Am Acad Dermatol. 2012 Nov;67(5):e179-85. doi: 10.1016/j.jaad.2011.05.038. Epub 2011 Jul 14.

PMID:
21752492
7.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
8.

Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction.

Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A.

Arthritis Rheum. 2005 Aug;52(8):2513-8.

9.

Adalimumab in the therapy of uveitis in childhood.

Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M.

Br J Ophthalmol. 2007 Mar;91(3):319-24. Epub 2006 Oct 11.

10.

Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.

Buisson A, Cuny JF, Barbaud A, Schmutz JL, Bigard MA, Guéant JL, Peyrin-Biroulet L.

Aliment Pharmacol Ther. 2012 May;35(10):1175-80. doi: 10.1111/j.1365-2036.2012.05082.x. Epub 2012 Apr 2.

11.

Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review.

Puig L, Morales-Múnera CE, López-Ferrer A, Geli C.

Dermatology. 2012;225(1):14-7. doi: 10.1159/000339864. Epub 2012 Aug 10. Review.

PMID:
22890275
12.

Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.

Fiorino G, Allez M, Malesci A, Danese S.

Aliment Pharmacol Ther. 2009 May 1;29(9):921-7. doi: 10.1111/j.1365-2036.2009.03955.x. Epub 2009 Feb 10. Review.

13.

Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis.

Collamer AN, Battafarano DF.

Semin Arthritis Rheum. 2010 Dec;40(3):233-40. doi: 10.1016/j.semarthrit.2010.04.003. Epub 2010 Jun 26. Review.

PMID:
20580412
14.

Histopathologic spectrum of psoriasiform skin reactions associated with tumor necrosis factor-α inhibitor therapy. A study of 16 biopsies.

Laga AC, Vleugels RA, Qureshi AA, Velazquez EF.

Am J Dermatopathol. 2010 Aug;32(6):568-73. doi: 10.1097/DAD.0b013e3181cb3ff7.

PMID:
20520526
15.

Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.

Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, Humbert P, Aubin F.

Joint Bone Spine. 2008 May;75(3):315-8. doi: 10.1016/j.jbspin.2007.06.011. Epub 2008 Feb 11.

PMID:
18329935
16.
17.

Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents.

Guerra I, Gisbert JP.

Expert Rev Gastroenterol Hepatol. 2013 Jan;7(1):41-8. doi: 10.1586/egh.12.64. Review.

PMID:
23265148
18.

Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?

Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W, Dolman KM, Wulffraat NM, van Suijlekom-Smit LW.

Ann Rheum Dis. 2011 Feb;70(2):337-40. doi: 10.1136/ard.2010.135731. Epub 2010 Nov 10.

PMID:
21068101
19.

Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases.

Ko JM, Gottlieb AB, Kerbleski JF.

J Dermatolog Treat. 2009;20(2):100-8. doi: 10.1080/09546630802441234. Review.

PMID:
18923992
20.

Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA.

Medicine (Baltimore). 2007 Jul;86(4):242-51.

Supplemental Content

Support Center